<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>CURE</h3></div><p><span class="main">"Clopidogrel in Patients with Acute Coronary Syndromes". The New England Journal of Medicine. 2001. 345(7):494-502.  </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/CURE>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa010746>Full Journal Article</a>
                                        </span></p><p><span class="main">Contents
1 Clinical Question
2 Bottom Line
3 Major Points
4 Guidelines
5 Design
6 Population
6.1 Inclusion Criteria
6.2 Exclusion Criteria
6.3 Baseline Characteristics
7 Interventions
8 Outcomes
8.1 Primary Outcomes
8.2 Secondary Outcomes
9 Safety
10 Subgroup Analyses
11 Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with acute coronary syndromes without ST-segment elevation, does the addition of clopidogrel to aspirin reduce the risk of cardiovascular events?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">In patients with acute coronary syndromes without ST-segment elevation, treatment with clopidogrel plus aspirin reduced the risk of cardiovascular death, myocardial infarction, or stroke compared with aspirin alone but increased the risk of major bleeding.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">The CURE trial demonstrated that the addition of clopidogrel to standard therapy with aspirin in patients with acute coronary syndromes without ST-segment elevation resulted in a significant reduction in major cardiovascular events. However, it also showed that the combination increased the risk of major bleeding, which physicians should consider when prescribing clopidogrel.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Guidelines recommend dual antiplatelet therapy with clopidogrel and aspirin for patients with acute coronary syndrome without ST-segment elevation, particularly in those not undergoing revascularization procedures.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Multicenter, double-blind, placebo-controlled trial
- N=12,562 
- Clopidogrel + aspirin (n=6259)
- Placebo + aspirin (n=6303)
- Setting: 482 centers in 28 countries
- Enrollment: 1998-2000
- Mean follow-up: 9 months
- Analysis: Intention-to-treat
- Primary outcomes: Composite of death from cardiovascular causes, nonfatal MI, or stroke; and the composite of the first primary outcome or refractory ischemia
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Inclusion Criteria
- Hospitalized within 24 hours after the onset of symptoms
- No ST-segment elevation
 </span></p><p><span class="main">Exclusion Criteria
- Contraindications to antiplatelet therapy
- High bleeding risk or severe heart failure
- Using oral anticoagulants
- Recent revascularization or glycoprotein IIb/IIIa receptor inhibitors
 </span></p><p><span class="main">Baseline Characteristics
- Similar across the groups
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Clopidogrel (300 mg loading dose, 75 mg daily) + aspirin (75 to 325 mg daily)
- Placebo + aspirin (75 to 325 mg daily)
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Primary Outcomes
- First primary outcome: 9.3% in clopidogrel group vs. 11.4% in placebo group (RR 0.80; 95% CI, 0.72 to 0.90; P<0.001)
- Second primary outcome: 16.5% in clopidogrel group vs. 18.8% in placebo group (RR 0.86, P<0.001)
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- In-hospital severe ischemia, recurrent angina, heart failure, and revascularization were also significantly lower with clopidogrel.
 </span></p><p><span class="main">Safety
- Major bleeding: 3.7% in the clopidogrel group vs. 2.7% in the placebo group (RR 1.38; P=0.001)
- Life-threatening bleeding: no significant difference 
 </span></p><p><span class="main">Subgroup Analyses
- Consistent benefits across various subgroups (e.g., different doses of aspirin, use of other medications, prior revascularization)
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- The original publication in NEJM </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>